Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-09
2009-10-06
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000
Reexamination Certificate
active
07598264
ABSTRACT:
Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R1?, R2?, R3?, R4? and R5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
REFERENCES:
patent: 6262055 (2001-07-01), Young et al.
patent: 6306891 (2001-10-01), Selnick et al.
patent: 6380249 (2002-04-01), Young et al.
patent: 6841558 (2005-01-01), Anthony et al.
patent: 6919351 (2005-07-01), Anthony et al.
patent: 6921759 (2005-07-01), Anthony et al.
patent: 7109186 (2006-09-01), Walker et al.
patent: 7169780 (2007-01-01), Crescenzi et al.
patent: 7211572 (2007-05-01), Miyazaki et al.
patent: 7217713 (2007-05-01), Crescenzi et al.
patent: 7232819 (2007-06-01), Di Francesco et al.
patent: 7279487 (2007-10-01), Egbertson et al.
patent: 7435734 (2008-10-01), Crescenzi et al.
patent: 7459452 (2008-12-01), Di Francesco et al.
patent: 2003/0055071 (2003-03-01), Anthony et al.
patent: 2003/0229079 (2003-12-01), Payne et al.
patent: 2004/0229909 (2004-11-01), Kiyama et al.
patent: 2005/0010048 (2005-01-01), Zhuang et al.
patent: 2005/0054645 (2005-03-01), Miyazaki et al.
patent: 2006/0052361 (2006-03-01), Miyazaki et al.
patent: 2007/0161639 (2007-07-01), Jones et al.
patent: 2008/0009490 (2008-01-01), Williams et al.
patent: 2008/0139579 (2008-06-01), Morrissette et al.
patent: 1422218 (2004-05-01), None
patent: WO 01/00578 (2001-01-01), None
patent: WO 02/30426 (2002-04-01), None
patent: WO 02/36734 (2002-05-01), None
patent: WO 02/55079 (2002-07-01), None
patent: WO 03/035076 (2003-05-01), None
patent: WO 03/035077 (2003-05-01), None
patent: WO 03/062204 (2003-07-01), None
patent: WO 2004/004657 (2004-01-01), None
patent: 2006/121831 (2006-11-01), None
Collins et al., FEBS letters, (Apr. 14, 2000) vol. 471, No. 2-3, pp. 169-172.
Office Action mailed Aug. 1, 2007, U.S. Appl. No. 10/587,601, filed Jul. 28, 2006.
Ratner, L., et al., “Complete Nucleotide Sequence of the AIDS Virus, HTLV-III”, Nature, vol. 313, pp. 277-284, (1985).
Toh, H., et al., “Close Structural Resemblance Between Putative Polymerase of a Drosphila Transposable Genetic Element 17.6 and Pol Gene Product of Moloney Murine Leukemia Virus”, EMBO Journal, vol. 4, No. 5, pp. 1267-1272, (1985).
Power, M.D., et al., “Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Retrovirus”, Science, vol. 231, pp. 1567-1572, (1986).
Pearl, L.H., et al., “A Structural Model for the Retroviral Proteases”, Nature, vol. 329, pp. 351-354, (1987).
Derwent Abstract No. 2003-300600/29, Abstract of WO 03/016275, “Compositions Containing New and Known Heterocyclic Ketone Compounds Useful as Antiviral Agents Especially for Treating HIV Infections (JPN)”.
Derwent Abstract, No. 2005-202383/21, Abstract of WO 05/016927, “New Bicyclic Nitrogen Containing Heterocyclic Dione Compounds are Integrase Inhibitors Used for Treating Viral Infections e.g. HIV Infection (JPN)”.
Maurin, C., et al., “Structure-Activity Relationships of HIV-1 Integrase Inhibitors—Enzyme-Ligand Interactions”, Current Medicinal Chemistry, vol. 10, pp. 1795-1810 (2003).
Declaration of Interference No. 105,655 between (i) Jones et al., U.S. Appl. No. 10/587,601, filed Jul. 28, 2006, and (ii) Miyazaki et al., US 7,211,572.
LaFemina et al. Requirement of Active Human Immunodeficiency Virus Type 1 Integrase Enzyme for Productive Infection of Human T-Lymphoid Cells, Journal of Virology, 1992, vol. 66, No. 12, pp. 7414-7419.
Fauci et al. “Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations”, Annals of Internal Medicine, 1984, vol. 100, No. 1, pp. 92-106.
Dean, et al. “Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene”, Science, 1996, vol. 273, pp. 1856-1862.
Mylonakis et al. “Laboratory Testing for Infection with the Human Immunodeficiency Virus: Established and Novel Approaches”, The American Journal of Medicine, 2000, vol. 109, pp. 568-576.
The Medical Letter on Drugs and Therapeutics, “Diagnostic Tests for HIV”, 1997, vol. 39, Issue 1008, pp. 81-83.
Constantine “Serologic tests for the retroviruses: approaching a decade of evolution”, AIDS, 1993, vol. 7, No. 1, pp. 1-13.
Mellors, et al. “Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection”, Annals of Internal Medicine, 1997, vol. 126, No. 12, pp. 946-954.
Selected papers from Interference No. 105,655 between U.S. Appl. No. 10/587,601 (Merck) and US 7,211,572 (Japan Tobacco)—Merck Amended Miscellaneous Motion 1 dated Nov. 10, 2008; Interlocutory Order dated Nov. 18, 2008, Granting Merck's Unopposed Revised Miscellaneous Motion 1; Redeclaration of Interference dated Nov. 18, 2008; Judgement dated Dec. 5, 2008.
Preliminary Amendment filed Nov. 7, 2007 in U.S. Appl. No. 11/920,032 (unpublished national phase application of WO 2006/121831).
Preliminary Amendment filed Mar. 24, 2008 in U.S. Appl. No. 11/920,032 (unpublished national phase application of WO 2006/121831).
Second Preliminary Amendment filed Feb. 2, 2009 in U.S. Appl. No. 12/316,027.
Preliminary Amendment filed Dec. 9, 2008 in U.S. Appl. No. 12/316,027.
U.S. Appl. No. 12/316,027, filed Dec. 9, 2008, unpublished application.
Angelaud Remy
Askin David
Cameron Mark
Dolling Ulf H.
Egbertson Melissa
Heber Sheldon O.
Merck & Co. , Inc.
Rahmani Niloofar
Seaman D. Margaret
Walton Kenneth R.
LandOfFree
HIV integrase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV integrase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV integrase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114651